Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

dobutamine (Rx)Brand and Other Names:

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

infusion solution, in D5W

  • 100mg/100mL
  • 200mg/100mL
  • 400mg/100mL

injectable solution

  • 12.5mg/mL
more...

Cardiac Decompensation

0.5-1 mcg/kg/min IV continuous infusion initially, then 2-20 mcg/kg/min; not to exceed 40 mcg/kg/min  

Low Cardiac Output (Off-label)

2-20 mcg/kg/min IV or IO; titrate to desired effect; not to exceed 40 mcg/kg/min 

Dosage Forms & Strengths

infusion solution, in D5W

  • 100mg/100mL
  • 200mg/100mL
  • 400mg/100mL

injectable solution

  • 12.5mg/mL
more...

Cardiac Decompensation

0.5-1 mcg/kg/min IV continuous infusion initially, then 2-20 mcg/kg/min; not to exceed 40 mcg/kg/min  

Next

Interactions

Interaction Checker

dobutamine and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            1-10%

            Tachyarrhythmia (~10%)

            Hypertension (7.5%)

            Eosinophilic myocarditis (≤7%)

            Premature ventricular beats (5%; dose related)

            Angina (1-3%)

            Dyspnea (1-3%)

            Fever (1-3%)

            Headache (1-3%)

            Nausea (1-3%)

            Palpation (1-3%)

            Frequency Not Defined

            Cardiac dysrhythmia

            Exacerbation of coronary arteriosclerosis

            Hypokalemia

            Injection-site reactions

            Syncope

            10- to 20-mm Hg increase in systolic blood pressure and increase in heart rate of 5 to 15 beats/min

            Previous
            Next

            Warnings

            Contraindications

            Hypersensitivity to drug or components

            Idiopathic hypertrophic subaortic stenosis

            Cautions

            To optimize hemodynamics, correct hypovolemia if needed

            Clinical experience with dobutamine following myocardial infarction has been insufficient to establish safety of drug for this use; there is concern that any agent that increases contractile force and heart rate may increase size of infarction by intensifying ischemia, but not known whether dobutamine does so

            Severe coronary artery disease (CAD)

            Hypertension common; hypotension may also occur

            May cause a marked increase in heart rate or blood pressure,especially systolic pressure; because dobutamine facilitates atrioventricular conduction, patients with atrial fibrillation are at risk of developing rapid ventricular response; in patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be used prior to institution of therapy with dobutamine; patients with pre-existing hypertension appear to face an increased risk of developing an exaggerated pressure response

            During administration of dobutamine, monitor blood pressure continuously; pulmonary wedge pressure and cardiac output should be monitored whenever possible to aid safe and effective infusion of dobutamine in 5% dextrose Injection, USP

            Ventricular ectopy exacerbation may occur

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy category: B

            Lactation: Unknown whether drug is excreted into breast milk; avoid use

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Strong beta1 and weak beta2/alpha effects, resulting in increased cardiac output, blood pressure, and heart rate, as well as decreased peripheral vascular resistance

            Absorption

            Onset: 1-10 min

            Duration: 10 min

            Time to peak effect: ~15 min

            Distribution

            Vd: 0.2 L/kg

            Metabolism

            Metabolized in tissues and liver by catechol-O-methyl transferase

            Metabolites: Glucuronide conjugate, 3-0-methylated dobutamine (inactive)

            Elimination

            Half-life: 2 min

            Clearance: 90 mL/kg/min

            Excretion: Urine

            Previous
            Next

            Administration

            IV Incompatibilities

            Solution: Sodium bicarbonate 5%

            Additive: Acyclovir, alteplase, aminophylline, bretylium(?), bumetanide, calcium chloride(?), calcium gluconate, diazepam, digoxin, floxacillin, furosemide, heparin(?), insulin, magnesium sulfate, phenytoin, potassium phosphates, sodium bicarbonate

            Syringe: Doxapram

            Y-site: Acyclovir, alatrofloxacin, alteplase, aminophylline, amphotericin B cholesteryl sulfate, cefepime, foscarnet, furosemide(?), heparin(?), indomethacin, phytonadione, piperacillin-tazobactam, thiopental, warfarin

            IV Compatibilities

            Solution: Most common solvents (D5/LR, D5/NS, D5W, LR, NS)

            Additive (partial list): Amiodarone, atropine, ciprofloxacin, dopamine, epinephrine, flumazenil, hydralazine, lidocaine, meperidine, morphine sulfate, nitroglycerin, nitroglycerin with nitroprusside(?), norepinephrine, potassium chloride(?), verapamil (incompatible at higher concentrations)

            Syringe: Caffeine citrate, heparin, ranitidine

            Y-site (partial list): Amiodarone, atracurium, calcium gluconate, ciprofloxacin, diazepam, diltiazem, dopamine, epinephrine, fentanyl, inamrinone, labetalol, lidocaine, lorazepam, magnesium sulfate, midazolam(?), morphine sulfate, nitroglycerin, norepinephrine, potassium chloride, propofol, sodium nitroprusside, tacrolimus, vasopressin, verapamil, zidovudine

            IV Preparation

            Solution: Dilute 250 mg in 250 mL of compatible solution to yield final concentration of 1000 mcg/mL; not to exceed 5000 mcg/mL

            IV Administration

            Infuse into large vein via infusion pump

            Storage

            Store intact vials at room temperature; protect from excessive heat or freezing conditions

            Diluted solutions may be stored for 24 hours

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.